The global microbiome therapeutics market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases and rising demand for personalized medicine. The upper GIT segment accounted for the largest share in the global microbiome therapeutics market in 2018, followed by lower GIT and microbiome therapeutic segments.
The upper GIT segment accounted for the largest share in the global microbiome therapeutics market in 2018, followed by lower GIT and microbiome therapeutic segments. The application segment that accounted for the largest share was inflammatory bowel disease (IBD) in 2018, followed by orphan drug and immunoncology applications. North America dominated this market with a share of 39% in 2018 due to high prevalence of chronic diseases such as IBD among its population coupled with high adoption rates of personalized medicine therapies across all age groups.
Some Of The Growth Factors Of This Market:
- The microbiome is a complex ecosystem that is essential for human health and well-being.
- The microbiome has been linked to many diseases, including obesity, diabetes, cancer, and inflammatory bowel disease.
- Microbiome therapeutics are being developed to treat these diseases by targeting the microbiome with probiotics or fecal transplants (FMT).
- FMTs have been shown to be effective in treating Clostridium difficile infections and ulcerative colitis in clinical trials; however, they are not yet approved by the FDA for this indication because of safety concerns about transferring other bacteria from the donor stool into the recipient's gut flora during FMTs.
- There are also concerns about antibiotic resistance developing as a result of using antibiotics to treat C difficile infections before FMTs can be performed; however, there is evidence that suggests that antibiotic use may not increase resistance rates if it is limited to patients who have failed treatment with metronidazole or vancomycin alone or in combination with other antibiotics such as fidaxomicin or bacitracin/colistin/metronidazole/vancomycin (BFMV).
Industry Growth Insights published a new data on “Microbiome Therapeutics Market”. The research report is titled “Microbiome Therapeutics Market research by Types (Upper GIT, Lower GIT, Microbiome Therapeutic), By Applications (Inflammatory Bowel Disease (IBD), Orphan Drug, Immuno-oncology, Others), By Players/Companies Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, C3 Jian, Rebiotix, MicroBiome Therapeutics LLC, Metabiomics, Ritter Pharmaceuticals, Symberix, OpenBiome, Azitra, Symbiotix Biotherapies, Osel, Metabogen, Microbiome Therapeutic”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Microbiome Therapeutics Market Research Report
By Type
Upper GIT, Lower GIT, Microbiome Therapeutic
By Application
Inflammatory Bowel Disease (IBD), Orphan Drug, Immuno-oncology, Others
By Companies
Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, C3 Jian, Rebiotix, MicroBiome Therapeutics LLC, Metabiomics, Ritter Pharmaceuticals, Symberix, OpenBiome, Azitra, Symbiotix Biotherapies, Osel, Metabogen, Microbiome Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Microbiome Therapeutics Market Report Segments:
The global Microbiome Therapeutics market is segmented on the basis of:
Types
Upper GIT, Lower GIT, Microbiome Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Inflammatory Bowel Disease (IBD), Orphan Drug, Immuno-oncology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Osel
- Metabogen
- Microbiome Therapeutic
Highlights of The Microbiome Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Upper GIT
- Lower GIT
- Microbiome Therapeutic
- By Application:
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Microbiome Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Microbiome Therapeutics is a biotechnology company focused on the development of novel therapeutics to improve patient health by restoring and maintaining the healthy balance of bacteria in the gut. The Company's lead product candidate, ALIMENTO, is a novel oral probiotic formulation that has been shown to restore and maintain the healthy balance of bacteria in the gut.
Some of the major players in the microbiome therapeutics market are Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, C3 Jian, Rebiotix, MicroBiome Therapeutics LLC, Metabiomics, Ritter Pharmaceuticals, Symberix, OpenBiome, Azitra, Symbiotix Biotherapies, Osel, Metabogen, Microbiome Therapeutic.
The microbiome therapeutics market is expected to grow at a compound annual growth rate of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Microbiome Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Microbiome Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Microbiome Therapeutics Market - Supply Chain
4.5. Global Microbiome Therapeutics Market Forecast
4.5.1. Microbiome Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Microbiome Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Microbiome Therapeutics Market Absolute $ Opportunity
5. Global Microbiome Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Microbiome Therapeutics Market Size and Volume Forecast by Type
5.3.1. Upper GIT
5.3.2. Lower GIT
5.3.3. Microbiome Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Microbiome Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Microbiome Therapeutics Market Size and Volume Forecast by Application
6.3.1. Inflammatory Bowel Disease (IBD)
6.3.2. Orphan Drug
6.3.3. Immuno-oncology
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Microbiome Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Microbiome Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Microbiome Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Microbiome Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Microbiome Therapeutics Demand Share Forecast, 2019-2026
9. North America Microbiome Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Microbiome Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Microbiome Therapeutics Market Size and Volume Forecast by Application
9.4.1. Inflammatory Bowel Disease (IBD)
9.4.2. Orphan Drug
9.4.3. Immuno-oncology
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Microbiome Therapeutics Market Size and Volume Forecast by Type
9.7.1. Upper GIT
9.7.2. Lower GIT
9.7.3. Microbiome Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Microbiome Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Microbiome Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Application
10.4.1. Inflammatory Bowel Disease (IBD)
10.4.2. Orphan Drug
10.4.3. Immuno-oncology
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Type
10.7.1. Upper GIT
10.7.2. Lower GIT
10.7.3. Microbiome Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Microbiome Therapeutics Demand Share Forecast, 2019-2026
11. Europe Microbiome Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Microbiome Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Microbiome Therapeutics Market Size and Volume Forecast by Application
11.4.1. Inflammatory Bowel Disease (IBD)
11.4.2. Orphan Drug
11.4.3. Immuno-oncology
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Microbiome Therapeutics Market Size and Volume Forecast by Type
11.7.1. Upper GIT
11.7.2. Lower GIT
11.7.3. Microbiome Therapeutic
11.8. Basis Point Share(BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Microbiome Therapeutics Demand Share, 2019-2026
12. Asia Pacific Microbiome Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Application
12.4.1. Inflammatory Bowel Disease (IBD)
12.4.2. Orphan Drug
12.4.3. Immuno-oncology
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Type
12.7.1. Upper GIT
12.7.2. Lower GIT
12.7.3. Microbiome Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Microbiome Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Microbiome Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Application
13.4.1. Inflammatory Bowel Disease (IBD)
13.4.2. Orphan Drug
13.4.3. Immuno-oncology
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Type
13.7.1. Upper GIT
13.7.2. Lower GIT
13.7.3. Microbiome Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Microbiome Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Microbiome Therapeutics Market: Market Share Analysis
14.2. Microbiome Therapeutics Distributors and Customers
14.3. Microbiome Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Seres Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Assembly Biosciences
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Synthetic Biologics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Interxon
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. PureTech
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Synlogic
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Enterome BioScience
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. 4D Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Second Genome
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AOBiome
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. C3 Jian
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Rebiotix
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. MicroBiome Therapeutics LLC
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Metabiomics
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Ritter Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Symberix
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. OpenBiome
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Azitra
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Symbiotix Biotherapies
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Osel
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
